Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 Dose-ranging Study in Essential Hypertension (Japan)
jRCT2080221236Phase 2
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in essential hypertension (4 arms), sponsored by Novartis. Primary endpoint: Efficacy of LCZ696 on blood pressure after 8 weeks.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080221236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221236.